Back to Newsroom

CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment

TÜBINGEN, Germany, 16 December 2013 – CureVac, a German clinical stage biopharmaceutical company, today announced that it has reached the targeted number of patients for its phase IIb clinical trial of the mRNA-based immunotherapy CV9104 in patients with prostate cancer within the anticipated timeline. To date CureVac has included more than 195 chemotherapy-naïve patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer in eight European countries into the study.